TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34569495

Group type: EXPERIMENTAL
Intervention: Increased extracorporeal blood flow rate (BFR) from 0 to 300 mL/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inversion of inlet and outlet lines connected to the catheters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal BFR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflow pressure and outflow pressure
Number of subjects: 0
Study: 32860344

Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 72

Group type: COMPARATOR
Intervention: BWL
Number of subjects: 72
Study: 36196650

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional block
Number of subjects: 50
Study: 32562337

Group type: EXPERIMENTAL
Intervention: Micro-needling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 30
Study: 32648985

Group type: EXPERIMENTAL
Intervention: Cernitin (4 capsules/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tadalafil (5 mg/d)
Number of subjects: 100
Study: 33127596

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (extended induction for 16 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (initial induction for 8 weeks)
Number of subjects: 0
Study: 34270189

Group type: EXPERIMENTAL
Intervention: Reinforcement of colorectal anastomosis (main group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Transabdominal reinforcement (main group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No transabdominal reinforcement (control group)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Transanal reinforcement (main group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No transanal reinforcement (control group)
Number of subjects: 115
Study: 36221799

Group type: EXPERIMENTAL
Intervention: Low dose levodopa/carbidopa eye drops (1.4 levodopa:0.34 carbidopa [μmoles/day], n=14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Standard dose levodopa/carbidopa eye drops (2.7 levodopa:0.68 carbidopa [μmoles/day], n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (in fellow eye)
Number of subjects: 29
Study: 32965047

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 159

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 159
Study: 35279384

Group type: EXPERIMENTAL
Intervention: SCS + PNFS
Number of subjects: 75

Group type: COMPARATOR
Intervention: SCS-only
Number of subjects: 75
Study: 35868341

Group type: EXPERIMENTAL
Intervention: Twice-daily dolutegravir with rifampicin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Twice-daily dolutegravir
Number of subjects: 37
Study: 33053252

Group type: EXPERIMENTAL
Intervention: DC/TMD instructional video
Number of subjects: 50

Group type: COMPARATOR
Intervention: DC/TMD manual (control group)
Number of subjects: 50
Study: 32221587

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate 15 mg weekly
Number of subjects: 4168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Baseline IL-6
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Baseline hsCRP
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Baseline LDLC
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Elevated levels of both cholesterol and inflammation (IL-6 and LDLC)
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Elevated levels of both cholesterol and inflammation (hsCRP and LDLC)
Number of subjects: 4168
Study: 35969360

Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 36273162

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy via teleconference (5 weekly sessions)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Active control group (access to 15 videos covering the same topics)
Number of subjects: 280
Study: 33247529

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum CJLP243), taken once daily from preoperative day 1 to day 21
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, taken once daily from preoperative day 1 to day 21
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum CJLP243)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35147724

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 35077331

Group type: EXPERIMENTAL
Intervention: 30 min warm-up
Number of subjects: 13

Group type: COMPARATOR
Intervention: 10 min warm-up
Number of subjects: 13
Study: 33588379

Group type: EXPERIMENTAL
Intervention: Aqua-cycling session in 18 °C (EXO18)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aqua-cycling session in 27 °C (EXO27)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aqua-cycling sessions (EXO18 and EXO27)
Number of subjects: 30
Study: 36301961

Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (folic acid, vitamins B12, B6)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (folic acid, vitamin B12)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (vitamin B6)
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Baseline CLT (>cutoff)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Baseline Absmax (>cutoff)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Cys and uHcy-thiolactone
Number of subjects: 1952
Study: 33630934

Group type: EXPERIMENTAL
Intervention: Asymmetric real-time feedback about step timing
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Asymmetric real-time feedback about step position
Number of subjects: 29

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 29
Study: 32103064

Group type: EXPERIMENTAL
Intervention: Physical Fitness (PF) measured with Chair Stand Test
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels (low, moderate, high)
Number of subjects: 6874

Group type: EXPERIMENTAL
Intervention: Physical Fitness (PF) and Physical Activity (PA) levels
Number of subjects: 6874
Study: 34454599

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment before alveolar bone grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: No orthodontic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 0
Study: 32623488

Group type: EXPERIMENTAL
Intervention: Non-surgical hypoPT patients
Number of subjects: 94
Study: 35789192

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33861211

Group type: EXPERIMENTAL
Intervention: CAREs + community-based rehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Community-based rehabilitation only
Number of subjects: 40
Study: 36328358

Group type: EXPERIMENTAL
Intervention: GLPG1205 100 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GLPG1205
Number of subjects: 68
Study: 33647373

Group type: EXPERIMENTAL
Intervention: Aluminium lactate/potassium nitrate/hydroxylapatite toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Potassium nitrate control toothpaste
Number of subjects: 0
Study: 32562153

Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 37
Study: 34536795

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33017755

Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR)
Number of subjects: 381
Study: 36017744

Group type: EXPERIMENTAL
Intervention: Warfarin (additional 18-month treatment)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo (additional 18-month treatment)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: PVO > 45% at PE diagnosis
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: sPAP > 56 mmHg at PE diagnosis
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: PVO > 14% at 6 months
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: sPAP > 34 mmHg at 6 months
Number of subjects: 371
Study: 33909759

Group type: EXPERIMENTAL
Intervention: Speech therapy (guidance, therapeutic techniques, airway protection maneuvers, orofacial myofunctional and vocal exercises, diet introduction)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SHAM treatment (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 32
Study: 33444934

Group type: EXPERIMENTAL
Intervention: risperidone + fish oil (FO) (EPA 740 mg and DHA 400 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: risperidone + placebo
Number of subjects: 46
Study: 34210727

Group type: EXPERIMENTAL
Intervention: Diabetes self-care intervention package
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 220
Study: 32495933

Group type: EXPERIMENTAL
Intervention: TBA ≥ 40.00 μmol/L
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TBA threshold for phototherapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TBA threshold for preterm birth
Number of subjects: 86
Study: 35014942

Group type: EXPERIMENTAL
Intervention: Biaxial ankle-foot orthosis (AFO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lateral wedge insole
Number of subjects: 31
Study: 34715908

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg Q2W
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 32332459

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lurasidone 240 mg/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lurasidone (both doses)
Number of subjects: 67
Study: 33470861

Group type: EXPERIMENTAL
Intervention: Traction-manipulation protocol
Number of subjects: 40
Study: 33839578

Group type: EXPERIMENTAL
Intervention: Chronic gingivitis
Number of subjects: 6544

Group type: COMPARATOR
Intervention: No chronic gingivitis (Control)
Number of subjects: 6544
Study: 34057858

Group type: EXPERIMENTAL
Intervention: Telepractice-led assessment
Number of subjects: 14

Group type: COMPARATOR
Intervention: In-person-led assessment
Number of subjects: 14
Study: 34854748

Group type: EXPERIMENTAL
Intervention: Optilume® drug-coated balloon (DCB)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Endoscopic management (control)
Number of subjects: 127
Study: 32150651

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 35091313

Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 7372

Group type: COMPARATOR
Intervention: Shorter-duration enoxaparin
Number of subjects: 7372
Study: 34474301

Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of natalizumab (dosing intervals extended from 4 to 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard dosing of natalizumab (4-week intervals)
Number of subjects: 30
Study: 33077341

Group type: COMPARATOR
Intervention: Peg–IFN–α2a 180 μg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 270 μg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 360 μg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 450 μg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study: 35793664

Group type: EXPERIMENTAL
Intervention: BUP + incentivized adherence and abstinence monitoring (n = 70)
Number of subjects: 141

Group type: COMPARATOR
Intervention: BUP in usual care (control, n = 71)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 34235736

Group type: EXPERIMENTAL
Intervention: High-quality recess environment
Number of subjects: 352
Study: 32296202

Group type: EXPERIMENTAL
Intervention: Half-thickness tragal cartilage graft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 40
Study: 34890563

Group type: EXPERIMENTAL
Intervention: SOFMER Activity Score (SAS) version 2 (v2)
Number of subjects: 101
Study: 33776375

Group type: EXPERIMENTAL
Intervention: Moviprep (Mp)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Prep Kit-C (Pc)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: IBD patients with Moviprep (Mp)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Non-IBD patients with Moviprep (Mp)
Number of subjects: 338
Study: 35325329

Group type: EXPERIMENTAL
Intervention: Fat loading (FL) with 250 ml of Ensure H® four hours before follow-up examination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-fat loading (non-FL)
Number of subjects: 20
Study: 32080009

Group type: EXPERIMENTAL
Intervention: BGS-7 spacer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Titanium cage with autologous local bone
Number of subjects: 62
Study: 35673948

Group type: EXPERIMENTAL
Intervention: Levetiracetam (20 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Phenobarbitone (20 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Phenobarbitone (20 mg/kg) followed by Levetiracetam
Number of subjects: 82
Study: 32600210

Group type: EXPERIMENTAL
Intervention: One-hit assembly technique
Number of subjects: 5

Group type: COMPARATOR
Intervention: Three-hits assembly technique at low loads (4 kN)
Number of subjects: 5
Study: 36482794

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC; 0.4 mg/g; n = 29)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal nicotine content (NNC; 15.8 mg/g; n = 31)
Number of subjects: 66
Study: 33399223

Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder Checklist for DSM-5
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness (Epworth Sleepiness Scale)
Number of subjects: 220
Study: 32468187

Group type: EXPERIMENTAL
Intervention: Metformin + Insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Insulin
Number of subjects: 0
Study: 35791748

Group type: EXPERIMENTAL
Intervention: Low oxygen (23%)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High oxygen (80% during induction and recovery, 40% during maintenance)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 34147345

Group type: EXPERIMENTAL
Intervention: Multicomponent program of active aging (2 weekly sessions of 1h of exercise for 4 months, monthly health education sessions, and 3 days of social activities)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Multicomponent program of active aging
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (regular tips)
Number of subjects: 102
Study: 32985410

Group type: EXPERIMENTAL
Intervention: No tympanomeatal flap approach (group A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Tympanomeatal flap approach (group B)
Number of subjects: 132
Study: 36006603

Group type: EXPERIMENTAL
Intervention: Wearable fitness trackers used for 12 weeks during CBT treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maladaptive exercise group (n = 17)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-maladaptive exercise group (n = 13)
Number of subjects: 30
Study: 34621497

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy (EMDR)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Writing Therapy (CBWT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 101
Study: 35440302

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 0
Study: 33773111

Group type: EXPERIMENTAL
Intervention: 25 µg vaccine (two-dose schedule)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: 50 µg vaccine (two-dose schedule)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: 25 µg vaccine (three-dose schedule)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: 50 µg vaccine (three-dose schedule)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo (two-dose schedule)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo (three-dose schedule)
Number of subjects: 950
Study: 33423318

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide 400 μg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of budesonide with oral statin (simvastatin 10 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In vitro experiments with budesonide and simvastatin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neutralisation of IL-10 with recombinant specific blocking antibody
Number of subjects: 44
Study: 32539810

Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLT2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH Insulin
Number of subjects: 0
Study: 36158699

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT) with a dose of 54 Gy in 27 fractions
Number of subjects: 116

Group type: COMPARATOR
Intervention: Postoperative concurrent chemoradiotherapy (POCRT) with a dose of 50.4 Gy in 28 fractions combined with chemotherapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups (PORT and POCRT)
Number of subjects: 116
Study: 33376119

Group type: EXPERIMENTAL
Intervention: Experimental calculus disruption solution (EXP‐955)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 25
Study: 34048613

Group type: EXPERIMENTAL
Intervention: iCBT intervention for anxiety and/or depression
Number of subjects: 241
Study: 33534342

Group type: EXPERIMENTAL
Intervention: Long-term SBP of 120-129 mmHg
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Long-term SBP of 130-139 mmHg
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Long-term SBP of 100-119 mmHg
Number of subjects: 3310

Group type: COMPARATOR
Intervention: Long-term SBP of at least 140 mmHg
Number of subjects: 3310
Study: 34563804

Group type: EXPERIMENTAL
Intervention: Binaural Sound Therapy (BST)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Music Therapy (MT)
Number of subjects: 34
Study: 32331029

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (dose not specified) for 12 weeks in ARTISTS 1
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (high or low dose, specific dosages not specified) for 8 weeks in ARTISTS 2
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (open-label, single-arm) for long-term safety/tolerability
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo for 12 weeks in ARTISTS 1
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo for 8 weeks in ARTISTS 2
Number of subjects: 266
Study: 35353052

Group type: EXPERIMENTAL
Intervention: PTSD Coach (intervention group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 179
Study: 34715032

Group type: EXPERIMENTAL
Intervention: M5717 (150 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (400 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (800 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (600 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (1000 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (1250 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (1800 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: M5717 (2100 mg)
Number of subjects: 88
Study: 33190521

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 84
Study: 36067484

Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane (PLM)
Number of subjects: 60
Study: 36449784

Group type: EXPERIMENTAL
Intervention: TDM‐621
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control (hemostatic forceps)
Number of subjects: 227
Study: 33655778

Group type: EXPERIMENTAL
Intervention: 70-gene signature (Mammaprint)
Number of subjects: 6693

Group type: EXPERIMENTAL
Intervention: Decision-analytic modeling approach
Number of subjects: 6693

Group type: COMPARATOR
Intervention: MINDACT trial report
Number of subjects: 6693
Study: 35396967

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cellulose (placebo)
Number of subjects: 12
Study: 34267242

Group type: EXPERIMENTAL
Intervention: Exercise (45 min of incline walking)
Number of subjects: 30
Study: 32840419

Group type: EXPERIMENTAL
Intervention: Accelerated Partial-Breast Irradiation (APBI) - 30 Gy in 5 once-daily fractions
Number of subjects: 520

Group type: COMPARATOR
Intervention: Whole-Breast Irradiation (WBI) - 50 Gy in 25 fractions with a tumor bed boost
Number of subjects: 520
Study: 35368768

Group type: EXPERIMENTAL
Intervention: Acupressure‐like stimulation and meditation over a 5 min period
Number of subjects: 65

Group type: COMPARATOR
Intervention: Rest during the same 5 min period
Number of subjects: 65
Study: 32623608

Group type: EXPERIMENTAL
Intervention: Experimental schedule group (ESG) - reduced-frequency nurse-led, consultant-supervised clinic
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional schedule group (CSG) - reviewed as per UK guidelines
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Experimental follow-up (EFU)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional follow-up (CFU)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Self-examination method of detection
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Melanoma-specific survival
Number of subjects: 207
Study: 34547340

Group type: EXPERIMENTAL
Intervention: Lidocaine plus Clonidine (LC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine plus Saline Solution (LS)
Number of subjects: 40
Study: 36028915

Group type: EXPERIMENTAL
Intervention: PEG + Mizone
Number of subjects: 270

Group type: COMPARATOR
Intervention: PEG + water
Number of subjects: 270